Clinical trials
Advanced Solid Tumor clinical trials
Below are recruiting advanced solid tumor clinical trials, each written for real people, not researchers. We’re tracking 1,373 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07374848RecruitingPhase 1
Study of ZL-6201 for sarcoma and some solid tumors
This trial tests a new drug called ZL-6201 for people with sarcoma or certain solid tumors that have spread or cannot be removed. It aims to see if the drug is safe and helps shrink tumors.
Los Angeles, CaliforniaAges 18 years+ - NCT07218003Enrolling by invitationPhase 1
Study of RNDO-564 alone or with pembrolizumab for bladder cancer
This trial tests an experimental drug, RNDO-564, either by itself or combined with another drug (pembrolizumab), for people with advanced bladder cancer or other solid tumors that have stopped responding to standard treatments. The goal is to see if it can shrink tumors or slow cancer growth.
San Francisco, CaliforniaAges 18 years+ - NCT07280832RecruitingPhase 1/Phase 2
JMT108 for advanced melanoma and urinary tract cancer
This study tests a new drug called JMT108 for advanced melanoma or urinary tract cancer. It may help your immune system attack the cancer, and the study is checking if it is safe and how well it works.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06397963Recruiting
Personalized immune cell therapy for advanced solid tumors
This study tests a new treatment using your body's own immune cells (called tumor-infiltrating lymphocytes) that are taken from your tumor, grown in a lab, and then put back into you. It's for people with advanced solid tumors who have run out of standard options.
Beijing, Beijing MunicipalityAges 18–70 - NCT06265025RecruitingPhase 1/Phase 2
GM103 injection for advanced solid tumors that can't be removed
This trial tests an experimental drug called GM103 that is injected directly into tumors. It is for people with advanced solid tumors that have not responded to other treatments and cannot be surgically removed.
Goyang-si, Gyeonggi-doAges 18 years+ - NCT06003621RecruitingPhase 2
Tiragolumab and atezolizumab for advanced solid tumors
This trial tests a combination of two immunotherapy drugs (tiragolumab and atezolizumab) for people with advanced solid tumors that have stopped responding to standard treatments or cannot be treated with available therapies. It may be an option if your tumor has certain immune-related markers.
Albury, New South WalesAges 18 years+ - NCT07533708RecruitingPhase 1
Testing HLX3902 for advanced cancers, especially prostate cancer
This study tests a new drug called HLX3902 in patients with advanced cancers that have stopped responding to standard treatments. The drug targets a protein called STEAP1 and may help slow or stop cancer growth.
NanchangAges 18 years+ - NCT06759649RecruitingPhase 1
Study of COM503 for advanced solid tumors
This trial tests a new drug called COM503 for people with advanced solid tumors that have not responded to or cannot be treated with standard therapies. It aims to see if the drug is safe and how well it works.
New Haven, ConnecticutAges 18 years+ - NCT04114136RecruitingPhase 2
Study tests pembrolizumab or nivolumab plus a diabetes-like drug
This Phase 2 study tests whether adding a metabolic (diabetes-related) medicine to an immune therapy (pembrolizumab or nivolumab) can better control certain solid tumors. It may help people whose standard treatment would usually be pembrolizumab or nivolumab alone.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT07482592RecruitingPhase 1
Study of TQB3205 for advanced solid tumors
This trial tests an experimental drug called TQB3205 for people with advanced solid tumors that have not responded to other treatments. The study will check if the drug is safe and how it affects the tumors.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07269145RecruitingPhase 1
Testing TQB3122 capsules in advanced solid tumors
This trial tests an experimental oral capsule (TQB3122) for safety and early signs of effectiveness in people with advanced solid tumors that have not responded to standard therapies. It is for patients who are relatively healthy and have specific cancer types like ovarian, breast, or prostate cancer.
Beijing, Beijing MunicipalityAges 18–75 - NCT04300556RecruitingPhase 1/Phase 2
Testing an antibody-drug for advanced certain cancers
This early-phase trial tests a treatment called MORAb-202, an antibody “delivery” drug, to see if it’s safe and can help shrink or control certain advanced cancers. It may help people whose tumors match the study’s specific cancer types and prior treatment history.
Tucson, ArizonaAges 18 years+ - NCT05691491RecruitingPhase 1/Phase 2
Temozolomide plus M1774 for advanced metastatic cancers
This Phase 1/2 trial tests a combination of temozolomide and M1774 to see how safe it is and whether it can help shrink advanced cancers that have spread. It focuses on certain tumor types and specific biomarker results, and it may be an option if standard treatments have been tried or aren’t possible.
Irvine, CaliforniaAges 18 years+ - NCT06380816RecruitingPhase 1/Phase 2
Study of UCB4594 for advanced cancers with HLA-G marker
This trial tests an experimental drug called UCB4594 for people with certain advanced cancers that have not responded to standard treatments. The goal is to see if the drug is safe and effective against tumors that have a specific marker called HLA-G.
LondonAges 18 years+ - NCT06697665RecruitingEarly Phase 1
LM103 vaccine with PD-1 for advanced solid tumors
This trial tests a new personalized cancer vaccine (LM103) combined with an immunotherapy drug (PD-1) for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if this combination is safe and can help shrink tumors.
China, Tianjin MunicipalityAges 18–75 - NCT06725758RecruitingPhase 1/Phase 2
First-in-human study of ODM-212 for advanced solid tumors
This study tests an experimental drug called ODM-212 for people with advanced solid tumors that have not responded to standard treatments. It may be especially relevant if your tumor has changes in the Hippo pathway (certain genes like NF2 or YAP/TAZ).
Los Angeles, CaliforniaAges 18 years+ - NCT00870129Recruiting
MRI mapping to plan radiation for certain brain tumors
This study uses MRI scans to find higher-risk areas in certain brain and other solid tumors and help plan radiation treatment. It also looks for changes in tumor “metabolites” (chemicals in the tumor) that may relate to how the tumor behaves.
New York, New YorkAges 18 years+ - NCT07744152RecruitingPhase 1
Testing a new drug for advanced solid tumours
This study tests a new drug called BI 3822971 for people with advanced cancer that has not responded to standard treatments. The goal is to find the best dose that is safe and well-tolerated.
LeuvenAges 18 years+ - NCT05615974RecruitingPhase 1/Phase 2
LM-101 injection study for advanced solid tumors
This Phase I/II study tests LM-101, a new injection, in adults with advanced solid cancers that have already been treated and kept growing. It aims to see how safe it is and whether it can shrink tumors or help people live longer.
Guangzhou, GuangdongAges 18 years+ - NCT06650566RecruitingPhase 1/Phase 2
Study of LM-299 for advanced solid tumors
This study tests a new drug called LM-299 for people with advanced solid tumors that haven't responded to standard treatments. The goal is to see if LM-299 is safe and effective.
Perth, Western AustraliaAges 18–80 - NCT04678648RecruitingPhase 1
Testing RSC-1255 in advanced cancers with RAS changes
This early study (Phase 1) tests a new drug, RSC-1255, in people with advanced or metastatic cancers that have RAS mutations. It’s mainly focused on whether the treatment can be given safely and at what dose, and to see if it may shrink tumors.
Los Angeles, CaliforniaAges 18 years+ - NCT07584824Recruiting
Cancer Care Laws and Modern Technology Survey
This survey asks cancer patients, their relatives, and healthcare workers in the UK about how well current cancer care laws work with today's technology. Your feedback helps shape future cancer care policies and practices.
TruroAges 18 years+ - NCT07705035RecruitingPhase 1
DBC-664 for adults with advanced solid tumors
This trial tests a new drug called DBC-664 for people with solid tumors that have come back or spread and cannot be removed by surgery. It may be an option if you have tried other treatments or if standard options are limited.
Denver, ColoradoAges 18 years+ - NCT07073534RecruitingPhase 1/Phase 2
A study of two drugs for advanced solid tumors
This trial tests two drugs combined—SHR-1501 and adbelizumab—for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the combination is safe and effective.
Guangzhou, GuangdongAges 18–75
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced solid tumor?
- Yes. Clin2 currently lists 1,373 recruiting advanced solid tumor studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced solid tumor trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced solid tumor trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.